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ABSTRACT 47 
 48 
Alexander Disease (AxD) is a fatal neurodegenerative disorder caused by mutations in glial 49 
fibrillary acidic protein (GFAP), which supports the structural integrity of astrocytes. Over 70 50 
GFAP missense mutations cause AxD, but the mechanism linking different mutations to disease-51 
relevant phenotypes remains unknown. We used AxD patient brain tissue and induced 52 
pluripotent stem cell (iPSC)-derived astrocytes to investigate the hypothesis that AxD-causing 53 
mutations perturb key post-translational modifications (PTMs) on GFAP. Our findings reveal 54 
selective phosphorylation of GFAP-Ser13 in patients who died young, independently of the 55 
mutation they carried. AxD iPSC-astrocytes accumulated pSer13-GFAP in cytoplasmic 56 
aggregates within deep nuclear invaginations, resembling the hallmark Rosenthal fibers observed 57 
in vivo. Ser13 phosphorylation facilitated GFAP aggregation and was associated with increased 58 
GFAP proteolysis by caspase-6. Furthermore, caspase-6 was selectively expressed in young AxD 59 
patients, and correlated with the presence of cleaved GFAP. We reveal a novel PTM signature 60 
linking different GFAP mutations in infantile AxD. 61 
 62 
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INTRODUCTION 93 
 94 
Alexander Disease (AxD) is a rare and invariably fatal neurological disorder that affects 95 
primarily infants and small children, but can also manifest later in life 
1-3
. Autosomal dominant 96 
gain-of-function mutations in GFAP, which encodes glial fibrillary acidic protein (GFAP), cause 97 
AxD 
3, 4
. GFAP is the major component of the intermediate filament (IF) cytoskeleton in 98 
astrocytes 
5
. The accumulation and incorporation of mutant GFAP within cytoplasmic aggregates 99 
called Rosenthal fibers (RFs), causes reactive gliosis, leading to secondary injury to neurons and 100 
non-neuronal cells 
6-9
. Silencing GFAP via antisense oligonucleotide intervention in vivo 101 
eliminates RFs, reverses the stress responses in astrocytes and other cell types, and improves the 102 
clinical phenotype in a mouse model of AxD 
10
. While the utility of GFAP as a key therapeutic 103 
target in AxD is clear, the molecular mechanisms for how AxD-associated GFAP missense 104 
mutations (affecting over 70 different residues on GFAP) lead to defective GFAP proteostasis 105 
are not well understood. Deciphering these mechanisms may yield novel interventions, not only 106 
for AxD patients, but also for patients with other diseases where IF proteostasis is severely 107 
compromised. 108 
 109 
Normal functioning IFs are stress-bearing structures that organize the cytoplasmic space, 110 
scaffold organelles, and orchestrate numerous signaling pathways. In contrast, dysfunctional IFs 111 
directly cause or predispose to over 70 tissue-specific or systemic diseases, including 112 
neuropathies, myopathies, skin fragility, metabolic dysfunctions, and premature aging
11
 113 
(www.interfil.org). Disease-associated IF proteins share two key molecular features: abnormal 114 
post-translational modifications (PTMs)
12
 and pathologic aggregation. The GFAP-rich RF 115 
aggregates that are hallmarks of AxD astrocytes bear strong similarities to pathologic aggregates 116 
of other IFs, including epidermal keratins
13
, simple epithelial keratins
14
, desmin
15
, vimentin
16
, 117 
neurofilaments
17
 and the nuclear lamins
18
. There are unique advantages to studying IF 118 
proteostasis mechanisms in the context of GFAP because of its restricted cellular expression, 119 
homopolymeric assembly mechanism, and because GFAP is the sole genetic cause of AxD as a 120 
direct result of its toxic gain-of-function accumulation and aggregation.  121 
 122 
Like all IF proteins, GFAP contains three functional domains: amino-terminal ‘head’ domain, 123 
central α-helical ‘rod’ domain and carboxy-terminal ‘tail’ domain 19. The globular head domain 124 
is essential for IF assembly and disassembly, which are regulated by various post-translational 125 
modifications, in particular phosphorylation 
20
. It was shown previously that phosphorylation of 126 
multiple sites in the head domain of GFAP (Thr-7, Ser-8, Ser-13, Ser-17 and Ser-34) regulates 127 
filament disassembly during mitosis and GFAP turnover in non-mitotic cells 
21-24
. Additionally, 128 
phosphorylation of GFAP has been observed after various injuries of the central nervous system 129 
(CNS) including kainic acid-induced seizures, cold-injury, and hypoxic-ischemic models, where 130 
phosphorylated GFAP is expressed in reactive astrocytes 
25-27
. These observations reveal that 131 
phosphorylation of GFAP is important for re-organization of the astrocyte IF cytoskeleton and 132 
plasticity in response to injury. However, it is not clear if, and how, abnormal GFAP 133 
phosphorylation compromises proteostasis and contributes to AxD pathogenesis. 134 
 135 
Here, we identified a critical phosphorylation site in the GFAP head domain that is selectively 136 
and strongly upregulated in the brain tissues of AxD patients who died very young, 137 
independently of the position of the disease mutation that they carried. Further, we show that this 138 
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site-specific phosphorylation promotes GFAP aggregation and is a marker of perinuclear GFAP 139 
aggregates associated with deep nuclear invaginations in AxD patient astrocytes, but not in 140 
isogenic control astrocytes. Finally, we demonstrate a correlation between site-specific GFAP 141 
phosphorylation and caspase cleavage in cells and in post-mortem brain tissue from AxD 142 
patients. Although our study does not establish a causal relationship between GFAP 143 
phosphorylation and caspase cleavage, we show that caspase-6 is a new marker for the most 144 
severe form of human AxD.  145 
 146 
Collectively, our results reveal a new PTM signature that is associated with defective GFAP 147 
proteostasis in the most severe form of AxD. Future interventional studies targeting these PTMs 148 
will determine whether they contribute to, or are the consequence of, disease severity. 149 
 150 
 151 
RESULTS 152 
Phosphorylation of Ser13 on GFAP is a marker of the most aggressive form of AxD. IFs 153 
undergo protein synthesis-independent turnover and re-organization to meet cellular demands
28
. 154 
PTMs are key in that process, as they regulate filament polymerization and depolymerization, 155 
protein-protein interactions, and oligomerization properties of IF proteins
12
. Of all known PTMs 156 
that regulate IFs, phosphorylation is the most ubiquitous and can facilitate or antagonize other 157 
types of PTMs via complex cross-talk mechanisms
20
. We hypothesized that AxD-associated 158 
GFAP missense mutations (Fig.1A) promote GFAP accumulation and aggregation by 159 
dysregulating site-specific phosphorylation. We extracted GFAP from post-mortem brain cortex 160 
tissue of 13 AxD patients, representing 10 different mutations (Supplemental File 1) and 3 non-161 
AxD controls (Supplemental File 2). GFAP from the insoluble high salt extracts (HSEs), 162 
prepared according to the procedure described in Fig.1-Supplement 1, was used in phospho-163 
proteomic analysis, revealing 12 unique phosphorylation sites on GFAP in AxD (Fig.1B-C). 164 
While the AxD-specific phospho-peptides localized to all three functional domains of GFAP 165 
(head, rod, tail), the most abundantly phosphorylated residue was a conserved serine (Ser13) 166 
in the head domain (Fig.1C-D).  167 
 168 
Strikingly, we found that the pSer13-GFAP peptide was selectively elevated in the cortex 169 
tissue from AxD patients who died very young (median age at death=1.7 years; range 0.5-14 170 
years) (Fig. 2A). Overall, we did not observe significant phosphorylation of GFAP in the 171 
control subjects (Figure 2-Source Data 1), or in AxD patients who lived 27-50 years (median 172 
age at death=38 years). Further, immunoblot analysis using a phospho-specific antibody 173 
(KT13)
29
 against pSer13-GFAP validated the mass spectrometry results in the AxD patients 174 
(Fig.2B-C). Although there is one notable outlier in each age group (Fig.2B lanes 3 and 11), 175 
our results suggest that pSer13-GFAP is primarily associated with the more aggressive, 176 
infantile form of AxD. Furthermore, the differences in phosphorylation are not a result of age, 177 
since pSer13 GFAP is generally not present in the brain lysates from non-AxD control 178 
subjects, regardless of age (Fig. 2D). 179 
 180 
Phospho-mimic mutation at Ser13 promotes GFAP aggregation. To determine the functional 181 
significance of pSer13 on GFAP filament organization, we analyzed the filament properties of 182 
non-phosphorylatable (S13A) and phospho-mimic (S13D and S13E) GFAP mutants. We 183 
optimized a transient over-expression system in the SW13 vimentin-negative adrenocarcinoma 184 
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cells (SW13vim-) to for this assay, which resulted in primarily filamentous WT GFAP and 185 
insoluble aggregated forms of common AxD mutants of GFAP (Figure 3-Figure Supplement 186 
1). Compared to wild-type (WT) GFAP, the S13D and S13E mutants assembled primarily into 187 
large aggregates, similar to the most common AxD-associated mutant R79H-GFAP (Fig.3A-B). 188 
S13A formed mostly filaments, although they appeared shorter compared to WT GFAP. To 189 
determine if the phospho-mimic mutation directly promotes aggregation, we compared the 190 
assembly properties of purified WT, S13A and S13D GFAP (Fig. 3C). Consistent with the 191 
phenotype observed in the transfected cells, the S13A mutant formed abnormally short filaments 192 
in vitro. In contrast, S13D was completely incapable of filament assembly, forming globular 193 
structures that were homogeneous in size and not aggregation-prone. Our results with the 194 
phospho-deficient and phospho-mimic mutants reveal that S13 is a key site that regulates the 195 
assembly properties of GFAP and that its phosphorylation status may modulate the dynamics 196 
between filaments and aggregates.  197 
 198 
Generation of AxD induced pluripotent stem cells (iPSCs) and isogenic controls. In order to 199 
explore the function of this phosphorylation event in a disease-relevant system, we used an in 200 
vitro human astrocyte model of AxD. We generated iPSCs using fibroblasts from a young 201 
AxD patient and characterized their pluripotency by immunofluorescence staining (Fig.4A). 202 
Karyotype analysis showed that there were no chromosomal abnormalities due to the 203 
reprogramming process (Figure 4-Supplement 1). To generate isogenic control cells, we 204 
corrected the heterozygous point mutation in GFAP (c.715C>T, p.R239C) using 205 
CRISPR/Cas9 mediated gene editing (Fig.4B). Representative chromatograms are shown for 206 
the original patient cells and the isogenic controls (Fig.4C). We also isolated ‘CRISPR 207 
control’ clones, which were edited on the wild-type GFAP allele, thereby retaining the AxD-208 
causing mutation and serving as an additional disease control for the gene editing procedure. 209 
Similar to the original patient cells, the edited cells were karyotyped and characterized for 210 
pluripotency (Figure 4- Supplement 1). We confirmed that there were no off-target effects 211 
due to the editing procedure (Supplemental File 3). 212 
 213 
GFAP accumulation and perinuclear aggregation into RF-like structures in AxD iPSC-214 
astrocytes. AxD, CRISPR control, and isogenic control iPSCs were differentiated to 215 
astrocytes (iPSC-astrocytes) via neural progenitors cells (NPCs), as described in the Methods 216 
and shown schematically in Fig.4D. After 54 days in culture, iPSC-astrocytes express 217 
classical astrocyte markers
30
, including alcohol dehydrogenase 1 family member L1 218 
(ALDH1L1), solute carrier family 1 member 3 (SLC1A3), excitatory amino acid transporter 2 219 
(EAAT2), Connexin 43 and GFAP (Figure 4-Figure Supplement 2). To assess if our model 220 
recapitulates key features of AxD, we analyzed total GFAP expression in the iPSC-astrocytes by 221 
immunoblot, and found that GFAP levels were significantly higher in the cells that carried the 222 
heterozygous GFAP point mutation (AxD patient and CRISPR control lines) relative to the 223 
isogenic controls (Fig. 4E-F). This is consistent with in vivo observations of GFAP levels in 224 
AxD patients
31
 and mouse models
32
. In addition, high molecular mass GFAP oligomers were 225 
present in the AxD iPSC-astrocytes, similar to what we observe when we ectopically express the 226 
R239C-GFAP mutant (Fig.5A). Finally, we observed by immunofluorescence staining that the 227 
AxD mutant iPSC-astrocytes form both GFAP filaments and perinuclear aggregates (Fig.5B), 228 
whereas the isogenic control iPSC-astrocytes form only GFAP filaments (Fig.5C). In vivo, 229 
GFAP antibodies stain the periphery, while DAPI stains the core of RFs
33, 34
. The in vitro-230 
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derived AxD iPSC-astrocytes display similar characteristics, with RF-like perinuclear 231 
aggregates staining positively for GFAP at their periphery and DAPI in the center (Fig. 5B).   232 
 233 
pSer13-GFAP marks the core of perinuclear GFAP aggregates localized within deep 234 
nuclear invaginations. Next, we determined if pSer13-GFAP was present in the AxD iPSC-235 
astrocytes, similar to what we observed in the human brain tissues. As shown in Fig.6A, 236 
pSer13-GFAP signal was detected strongly within the core of the perinuclear GFAP 237 
aggregates of AxD iPSC-astrocytes. Somewhat surprisingly, we also observed pSer13-GFAP 238 
signal in the isogenic control cells, possibly triggered by the in vitro culture conditions. 239 
Nevertheless, unlike AxD astrocytes, in the isogenic control astrocytes pSer13-GFAP 240 
organization was filamentous and paralleled that of total GFAP. Therefore, the in vitro iPSC-241 
astrocyte model reveals that, only in the presence of the AxD disease mutation, pSer13-GFAP 242 
is incorporated within the core of perinuclear inclusions. While in all AxD cells pSer13 signal 243 
was detected in the aggregates, we also observed cells with pSer13-positive diffuse 244 
cytoplasmic staining and filaments, likely reflecting different states of the GFAP network 245 
(Figure 6-Supplement 1). Furthermore, the pSer13-positive GFAP aggregates appeared 246 
adjacent to prominent nuclear invaginations (Fig.6A). Nuclear deformations, similar to what 247 
we observe in the AxD iPSC-astrocytes, are also present in RF-bearing astrocytes in AxD 248 
human brain
34
. To determine whether the perinuclear aggregates compromised the nuclear 249 
envelope, we examined the AxD iPSC-astrocytes by electron microscopy. While we observed 250 
filamentous bundles on the cytoplasmic side of the nuclear invaginations, the nuclear 251 
envelope appeared intact (Fig.6B). Thus, pSer13-GFAP marks cytoplasmic GFAP aggregates 252 
adjacent to nuclear invaginations. It should be noted that the perinuclear aggregates 253 
containing disorganized GFAP filaments are not identical to the electron-dense RFs that are 254 
seen in post-mortem patient brain, but that they may reflect an intermediate state of GFAP 255 
accumulation.  256 
 257 
Phosphorylation at Ser13 promotes caspase-mediated cleavage of GFAP. To understand the 258 
mechanism for how GFAP phosphorylation may promote GFAP aggregation, we conducted a 259 
biochemical analysis of the S13A, S13D and S13E GFAP mutants. In line with our 260 
immunofluorescence result (Fig.3A), we observed an increase in high-molecular-mass ~100kDa 261 
GFAP in the phospho-mimic mutant by immunoblot analysis (Fig.7A). However, more 262 
strikingly, we observed increased levels of a cleaved GFAP fragment (24kDa) in S13D and 263 
S13E, which was significantly lower in WT- and S13A-GFAP (Fig.7A-B). Cleavage of GFAP 264 
by caspase-6 in vitro generates two fragments of 24 and 26 kDa size
35
. The 24 kDa C-terminal 265 
fragment is recognized by the monoclonal GA5 antibody, 
35
 which was used here. Therefore, we 266 
tested the effect of a peptide inhibitor of caspase-6 (Ac-VEID-CHO), and found that it 267 
significantly reduced the amount of cleaved S13D-GFAP (Fig.7C-D). Furthermore, we observed 268 
augmented cleavage of S13D-GFAP when combined with an AxD-causing mutation 269 
(S13D/R79H double mutant), and this was also blocked by the caspase-6 inhibitor (Fig.7C-D). 270 
Further analysis of the AxD mutant R79H in the transfection system revealed phosphorylation 271 
not only at S13, but also at nearby Y14, S16, and S17 (Figure 7-Supplement 1 and Source 272 
Data 1). Of note, mutagenesis of S16 and S17 to non-phosphorylatable alanines reduced both the 273 
cleavage and oligomerization of R79H (Figure 7-Supplement 1). Phospho-motif analysis 274 
revealed that S13, S16 and S17 are part of a segment in the GFAP head domain that is a potential 275 
target for several kinases (Supplemental File 4). Candidate kinases include casein kinase 2 276 
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(CK2), protein kinase A (PKA), PKC, MAP kinase activated protein kinase 2 (MAPKAP2), and 277 
glycogen synthase kinase 3 (GSK3). These data suggest that phosphorylation of Ser13 (and 278 
nearby S16/17) may promote caspase-6-mediated cleavage of GFAP in the context of AxD 279 
mutations. In line with that, we observe increased levels of cleaved GFAP (upon normalization 280 
for total GFAP) in the AxD iPSC-astrocytes compared to isogenic control astrocytes (Fig.7E), 281 
along with intense caspase-6 staining within perinuclear GFAP aggregates in AxD iPSC-282 
astrocytes, but not isogenic control astrocytes (Fig.7F).  283 
 284 
Interference with GFAP cleavage by caspase-6 partially reduces aggregation of the 285 
phospho-mimic mutant S13D. To determine how blocking GFAP cleavage affects aggregation, 286 
we performed site-directed mutagenesis to block cleavage at D225E. As shown in Fig. 8A-B, the 287 
D225E mutation reduced cleavage of S13D GFAP by >90%. This resulted in partial rescue of 288 
filament structure in S13D, although the D225E mutation on its own caused significant filament 289 
bundling and perinuclear structures that resembled large aggregates (Fig. 8C-D). We also tested 290 
the effect of the caspase-6 inhibitor Ac-VEID-CHO, and found that it reduced both the size of 291 
the S13D aggregates (Fig. 8E) and the presence of ~100kDa high-molecular-mass (hmm) GFAP 292 
oligomers (Fig 8F-G). However, similar to the mutagenesis experiment, filament bundles were 293 
observed in WT and S13D GFAP treated with Ac-VEID-CHO, suggesting that caspase-6 294 
regulates both aggregation and normal GFAP filament re-organization.  295 
 296 
Caspase-6 expression and GFAP cleavage are upregulated in AxD patients. Caspase-6 is not 297 
highly expressed in the normal human brain, especially after birth
36
. Therefore, we wanted to 298 
examine its expression in the context of AxD. Using immunoblot analysis of total brain lysates, 299 
we found that caspase-6 is expressed in the brain tissue from all 8 AxD patients who died very 300 
young, but is essentially undetectable in the patients who survived longer (Fig.9A). To ensure 301 
caspase-6 expression is not simply more abundant in young individuals, we compared brain 302 
lysates from young and old AxD patients to non-AxD control brains from age-matched 303 
individuals, and observed a significant increase in caspase-6 expression selectively in young 304 
AxD patients, but not in the other groups (Fig.9B-C).  305 
 306 
Next we asked whether AxD patients, particularly young AxD patients that exhibit more pSer13-307 
GFAP and caspase-6 expression, also displayed increased GFAP cleavage. To determine the 308 
extent of caspase-6-cleaved GFAP in AxD patient brains, we utilized an antibody that 309 
specifically recognizes N-terminally caspase-6-cleaved GFAP (D225)
35
. We detected cleaved 310 
GFAP in extracts from AxD patient brains, and we observed a significant increase in the amount 311 
of D225 signal in young AxD patients, which paralleled the increased pSer13 signal in these 312 
samples (Fig. 9D-E). In agreement with the biochemical evidence, brain tissues from young 313 
AxD patients stained intensely for cleaved GFAP, while the signal was significantly weaker in 314 
AxD patients who were older (Fig.9F, and Figure 9-Supplement 1). The signal was particularly 315 
strong around perinuclear areas and surrounded circular structures that stained positive for DAPI 316 
(Fig.9F, bottom panels), similar to what we observed in the AxD iPSC-astrocytes. Thus, our 317 
results show that caspase-6 expression in AxD patient brain tissue parallels the presence of 318 
cleaved GFAP, and both are selectively and significantly elevated in patients who succumbed to 319 
the disease very early in life.  320 
 321 
 322 
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DISCUSSION 323 
 324 
Our study reveals that missense mutations, affecting discrete domains on the GFAP molecule, 325 
share a common PTM signature that is associated with compromised GFAP proteostasis in the 326 
severe form of AxD. Using patient brain tissue and human iPSC-derived AxD astrocytes, we 327 
show that head domain phosphorylation promotes defective filament assembly and perinuclear 328 
accumulation and incorporation of mutant GFAP within nuclear invaginations. By taking an 329 
unbiased mass spectrometry proteomic approach, we were able to identify GFAP phospho-330 
peptides that were selectively elevated in human AxD brain tissue, and subsequently validated 331 
these results using a phospho-specific antibody against the most abundant epitope (pSer13-332 
GFAP). We demonstrate the importance of the Ser13 site for GFAP assembly in vitro and in 333 
cells. Phospho-mimetic mutation S13D completely abolished the ability of GFAP to form 334 
filaments in vitro, without leading to aggregation. In transfected SW13vim- cells, phospho 335 
mimic S13D-and S13E-GFAP mutants formed highly abnormal perinuclear aggregates that 336 
correlated with increased cleavage of GFAP by caspase-6. We detect a dramatic increase in 337 
caspase-6 expression, in association with Ser13 phosphorylation and cleavage of GFAP, in the 338 
brain tissue of AxD patients who succumbed to the disease very early in life. While the N-339 
terminal caspase-6 fragment of GFAP promotes filament aggregation in vitro
35
, presently we do 340 
not have direct evidence of cause and effect between caspase-6 cleavage and GFAP aggregation 341 
in AxD patient cells. Nevertheless, our current findings provide a basis for exploring PTM-based 342 
diagnostic and potential therapeutic strategies in AxD.  343 
 344 
Our study does not address whether Ser13 phosphorylation directly promotes caspase cleavage 345 
of GFAP, or if these two PTMs are independent markers of an increased cellular stress response 346 
in AxD. One possibility is that Ser13 phosphorylation destabilizes the filament structure, thereby 347 
promoting access of caspase-6 to the rod domain Asp225 residue, where the cleavage occurs. 348 
Another likely possibility is that the increased cleavage of GFAP is an indirect result of stress-349 
dependent caspase-6 activation in the more severe form of AxD. This is supported by previous 350 
studies showing that AxD mutations promote activation and nuclear accumulation of p53
7
, which 351 
can directly induce caspase-6 expression
37
. Future studies in AxD iPSC-astrocytes and animal 352 
models will be required to determine the timing of GFAP phosphorylation and caspase-6 353 
activation in relationship to GFAP cleavage and aggregation. 354 
 355 
Given our findings that pSer13-GFAP is enriched in the most aggressive form of AxD, 356 
monitoring the levels of this phospho-epitope (in addition to total GFAP) in AxD patient 357 
cerebrospinal fluid or blood may provide added sensitivity for disease activity 
31
. 358 
Phosphorylation of Ser13 by protein kinase C and cAMP-dependent protein kinase was initially 359 
described in vitro using purified recombinant GFAP
38
. In the presence of active kinases, Ser-13 360 
phosphorylation occurred in conjunction with phosphorylation at three additional sites (Thr-7, 361 
Ser-8, and Ser-34). Phosphorylation of monomeric GFAP at these sites prevented filament 362 
assembly, while phosphorylation of in vitro assembled GFAP filaments led to their 363 
disassembly
38
. Using the same antibody to pSer13-GFAP that we used in this paper (clone 364 
KT13) it was later shown that Aurora-B and Rho-associated kinase phosphorylate GFAP in 365 
cultured astrocytoma cells during mitosis
24
. This may bear relevance to AxD, since human and 366 
mouse AxD astrocytes with RFs display mitotic abnormalities 
34
. However, it was also shown 367 
using knock-in mice with the human GFAP head domain that, in vivo, the distribution of pSer13 368 
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localization was not limited to mitotic astrocytes, but that select astrocyte populations within 369 
multiple regions were pSer13 positive, such as those in the olfactory bulb, subpial regions, and 370 
subventricular zone 
26, 39
. Interestingly, the regional distribution of pSer13 largely overlaps with 371 
areas that are known to be most enriched in RFs in the AxD mouse model
39
. Therefore, this 372 
particular phosphorylation event on GFAP may occur during mitosis, or in phenotypically 373 
distinct astrocyte populations. This remains to be addressed in the future using the appropriate 374 
model systems, as over-expression studies in cancer cell lines (such as the SW13vim- cells we 375 
used here) may not be truly reflective of the signaling that occurs in astrocytes. In particular, it 376 
remains to be resolved whether phosphorylation of GFAP on Ser13 is part of a sequentially 377 
priming phosphorylation cascade involving nearby Ser16/17 (as predicted by the kinase motif 378 
analysis) or if Ser16/17 phosphorylation is unique to the SW13 over-expression system. 379 
Importantly, identifying the relevant in vivo kinase(s) that phosphorylate GFAP in human AxD 380 
may lead to potential novel interventions via kinase inhibition.   381 
 382 
Caspase-mediated proteolysis of IF proteins is an important mechanism by which the filament 383 
networks re-organize during apoptosis. Although multiple effector caspases are capable of 384 
cleaving IF proteins, caspase-6 is frequently implicated in cleavage at a conserved motif within 385 
the linker L12 region of the rod domain, which results in the generation of two fragments of 386 
similar sizes. This was initially demonstrated to be the case for the type I keratins
40
, and later 387 
shown to also occur on vimentin
41
, desmin
42
, A-type lamins
43
, and GFAP
5
. Caspase-6 cleavage 388 
of GFAP at 222VELD225 in vitro generates an N-terminal 26kDa fragment and a C-terminal 389 
24kDa fragment. The N-terminal fragment directly impairs assembly of full-length GFAP and 390 
promotes aggregation in vitro 
44
. Using a specific antibody recognizing the N-terminal GFAP 391 
fragment (D225), we show here that GFAP cleavage is significantly increased in AxD tissues 392 
from patients presenting with an aggressive form of AxD, and that this parallels elevated 393 
expression of caspase-6. This could suggest that misregulation of caspase-6 may contribute to the 394 
severity of AxD. However, we were not able to demonstrate in cells that inhibition of caspase-6, 395 
or mutagenesis of the cleavage site on GFAP, can resolve aggregate formation. These results 396 
point to a more complex function for caspase-6, likely involving cytoskeletal remodeling in 397 
response to stress.  398 
 399 
Indeed, caspase-6 upregulation has been reported in other neurodegenerative diseases involving 400 
protein aggregation, including Huntington’s Disease (HD) and Alzheimer’s Disease (AD) 45-47.  401 
Similar to GFAP, there is a caspase-6 cleavage site on the aggregation-prone proteins in both AD 402 
(amyloid precursor protein) and HD (huntingtin). Furthermore, in caspase-6 cleavage-resistant 403 
genetic mouse models of both HD and AD, neuronal dysfunction and degeneration are rescued 404 
48-50
. Caspase-6 can promote neurodegeneration via induction of neuronal apoptosis or axon 405 
pruning
51
. However, the functions of caspase-6 in astrocytes are not clear. In the context of 406 
human AxD it still remains to be determined which astrocyte populations express caspase-6, and 407 
whether it promotes apoptosis or performs a non-apoptotic role, such as sculpting the 408 
cytoskeletal architecture in reactive astrocytes. Based on our demonstration that caspase-6 409 
localizes within the perinuclear GFAP inclusions in the AxD iPSC-astrocytes, it is intriguing to 410 
speculate that, similar to keratin inclusions in epithelial cells
52
, RFs sequester active caspases 411 
away from other cellular substrates and may protect reactive astrocytes from apoptosis.  412 
 413 
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Recently, iPSC-derived patient astrocyte models have emerged as an important system for 414 
dissecting the cellular mechanisms in AxD. For example, these novel tools have revealed that 415 
AxD astrocytes have defects in the secretory pathway, impaired ATP release, and attenuated 416 
calcium waves
9
; that they inhibit oligodendrocyte precursor cell proliferation
8
, providing a 417 
potential mechanistic explanation for the degeneration of white matter observed in patients; and 418 
that they have defects in mechanotransduction signaling pathways
53
. A novel aspect of the AxD 419 
astrocyte cell model that we generated in our study is the perinuclear accumulation of pSer13-420 
GFAP that was associated with prominent nuclear abnormalities. As such, these patient-derived 421 
cells replicate a key phenotypic characteristic of RF-bearing AxD astrocytes in vivo, since 422 
nuclear invaginations have been described in electron microscopy studies of AxD mouse models 423 
and AxD patient cortex 
34
. Another important parallel is that the GFAP inclusions we observe in 424 
the AxD patient astrocytes in vitro stain positive for DAPI, and it was shown that DAPI is a 425 
reliable and sensitive marker of RFs in human and mouse brain
34
. Therefore patient-derived 426 
iPSC-astrocytes provide a unique model system to investigate cytoplasmic-nuclear mechanics in 427 
AxD.   428 
 429 
Invaginations of the nucleus, such as those we observe here, have been described in 430 
physiological and pathological states 
54
. Control of nuclear shape is critical for regulation of gene 431 
expression and response to mechanotransduction signals 
55
. The effects of impaired nuclear 432 
morphology can be very severe, as evidenced by mutations in lamin A that lead to defective 433 
nuclear morphology in Hutchinson-Gilford Progeria Syndrome (HGPS), where patients 434 
experience accelerated aging
56
. An elegant study combining multiple 3D imaging strategies 435 
established a direct link between intermediate filaments, actin and the nuclear envelope within 436 
nuclear invaginations, and genetic evidence indicates that filamentous actin may play a role in 437 
generating these structures 
57, 58
. It is hypothesized that nuclear invaginations provide localized 438 
control of gene expression and nuclear-cytoplasmic transport deep within the nucleus since they 439 
have been found to contain calcium receptors and nuclear pores 
54
. Our study provides the first 440 
link between abnormal cytoplasmic PTM processing and perinuclear accumulation of mutant 441 
GFAP with nuclear defects, setting the stage to address how nucleo-cytoskeletal coupling is 442 
adversely impacted by defective IF proteostasis in AxD and related human diseases. 443 
 444 
MATERIALS & METHODS 445 
 446 
Key Resources Table 447 
 448 
Reagent type (species) 
or resource 
Designation 
Source or 
reference 
Identifiers 
Additional 
information 
gene (human) GFAP NA Gene ID: 2670   
cell line (human) 
R239C-GFAP 
fibroblasts from 
AxD patient 
Coriell Institute GM16825 Brenner et al. 
Nature Genet. 2001 
cell line (human) 
R239C-GFAP 
induced 
pluripotent stem 
cells 
Generated in the 
study 
  
Generation of the 
AxD iPSCs (R239C-
GFAP) is described 
in the Methods 
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below. Cells can be 
obtained by 
contacting the 
corresponding 
author. 
cell line (human) 
R239R-GFAP 
isogenic control 
induced 
pluripotent stem 
cells 
Generated in the 
study 
  
Generation of the 
AxD iPSCs (R239C-
GFAP) is described 
in the Methods 
below. Cells can be 
obtained by 
contacting the 
corresponding 
author. 
cell line (human) SW13 vim- Sarria, A.J et al. 
J Cell Sci 1994 
    
biological sample (human) 
Human brain 
specimens 
NIH 
NeuroBioBank 
Listed in 
Supplemental Files 1 
and 2 
  
antibody rabbit anti-GFAP Agilent/DAKO Clone Z0334 
Dilution = 1:10,000 
immunoblot, 1:500 
immunofluorescence 
antibody 
rabbit anti-
caspase-6 
Cell Signaling 
Technology 
Cat # 9762 
Dilution = 1:1,000 
immunoblot 
antibody 
rabbit anti-
caspase-6 
abcam Cat # ab185645 
Dilution = 1:100 
immunofluorescence 
antibody rabbit anti-D225 PMID: 24102621   
gift from Dr. Ming 
Der Perng, Dilution 
= 1:5,000 
immunoblot 
(overnight), 1:150 
immunofluorescence 
antibody 
mouse anti-
GFAP 
Sigma 
Clone GA5, Cat # 
G3893 
Dilution = 1:3,000 
immunoblot, 1:300 
immunofluorescence 
antibody 
mouse anti-
pSer13 GFAP 
PMID: 8647894   
gift from Dr. Masaki 
Inagaki, Dilution = 
1:500 immunoblot 
(overnight), 1:20 
immunofluorescence 
antibody 
mouse anti-pan 
Actin 
NeoMarkers Cat #  MS-1295 
Dilution = 1:3,000 
immunoblot 
antibody 
mouse anti-Tra-
1-60 
ThermoFisher Cat# 41-1000 Dilution = 1:300 
antibody 
mouse anti-Tra-
1-81 
ThermoFisher Cat# 41-1100 Dilution = 1:300 
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antibody 
mouse anti-
SSEA4 
ThermoFisher Cat#41-4000 Dilution = 1:300 
antibody rabbit anti-Oct4 abcam Cat# ab19857 Dilution = 1:40 
antibody rabbit anti-Sox2 ThermoFisher Cat# 48-1400 Dilution = 1:125 
antibody 
Alexa 488-
conjugated goat 
anti-mouse 
ThermoFisher Cat# A32723 Dilution = 1:500 
antibody 
Alexa 488-
conjugated goat 
anti-rabbit 
ThermoFisher Cat# A32731 Dilution = 1:500 
antibody 
Alexa 594-
conjugated goat 
anti-mouse 
ThermoFisher Cat# A32742 Dilution = 1:500 
antibody 
Alexa 594-
conjugated goat 
anti-rabbit 
ThermoFisher Cat# A32740 Dilution = 1:500 
recombinant DNA reagent 
pCMV6-XL6-
GFAP 
Origene Cat# SC118873   
peptide, recombinant 
protein 
TrueCut Cas9 
Protein v2 
ThermoFisher Cat# A36499   
commercial assay or kit 
Precision gRNA 
Synthesis Kit 
ThermoFisher Cat# A29377   
commercial assay or kit 
Agilent 
Quikchange II 
Agilent Cat# 200524   
commercial assay or kit Rneasy Kit Qiagen Cat# 74104   
commercial assay or kit 
Taqman 
Scorecard 
ThermoFisher Cat# A15870   
chemical compound, drug ECL Reagents Perkin Elmer NEL103E001EA   
chemical compound, drug Ac-VEID-CHO Millipore Sigma A6339   
software, algorithm 
CRISPR off-
target  
PMID: 27380939 
http://crispor.tefor.net/ 
  
 449 
Antibodies. The following antibodies were used: rabbit anti-GFAP (DAKO Agilent, Santa 450 
Clara, CA, Z0334), rabbit anti-caspase-6 (Cell Signaling Technologies, Danvers, MA, 9762), 451 
rabbit anti-Caspase-6 (abcam, Cambridge, UK, ab185645), rabbit anti-D225
35
, mouse anti-GFAP 452 
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(Sigma, GA5), mouse anti-pSer13-GFAP (KT13
29
), mouse anti-pan Actin, mouse anti-Tra-1-60, 453 
mouse anti-SSEA4, rabbit anti-Oct4, rabbit anti-Sox2, and Alexa 488- and Alexa 594-congujated 454 
goat anti mouse or rabbit antibodies (Thermo Fisher Scientific, Waltham, MA).  455 
 456 
Cell lines. SW13vim- cells were provided by Dr. Bishr Omary and cultured in DMEM with 10% 457 
fetal bovine serum and 1% penicillin-streptomycin. Authentication of the cell line was done by 458 
short tandem repeat (STR) profiling by ATCC. Fibroblasts from a male 6-year old type I AxD 459 
patient were obtained from the Coriell institute (Camden, NJ). Sanger sequencing was performed 460 
to confirm the AxD mutation was present in the cells (c.715C>T; p.Arg239Cys). The cell lines 461 
used tested negative for mycoplasma contamination, as assayed using the Universal Mycoplasma 462 
Detection Kit (ATCC 30-1012K).  463 
 464 
Human brain tissues. De-identified post-mortem fresh-frozen and fixed AxD patient and 465 
control brain tissues were provided by the NIH NeuroBioBank and are described in 466 
Supplemental Files 1 and 2.  467 
 468 
Mass Spectrometry. Sample Preparation: HSEs from AxD patient post-mortem brain cortex 469 
tissue were prepared as described previously59, 60 and in Supplemental Fig.1, then subjected to 470 
SDS-PAGE followed by Coomassie stain. Bands corresponding to GFAP were excised and the 471 
proteins were reduced, alkylated, and in-gel digested with trypsin overnight at 37˚C. Peptides 472 
were extracted, desalted with C18 spin columns (Pierce – Thermo Fisher Scientific) and dried via 473 
vacuum centrifugation. Peptide samples were stored at -80˚C until further analysis. LC-MS/MS 474 
Analysis: The peptide samples were analyzed by LC/MS/MS using an Easy nLC 1200 coupled to 475 
a QExactive HF mass spectrometer (Thermo Fisher Scientific). Samples were injected onto an 476 
Easy Spray PepMap C18 column (75 μm id × 25 cm, 2 μm particle size) (Thermo Fisher 477 
Scientific) and separated over a 1hr method. The gradient for separation consisted of 5–40% 478 
mobile phase B at a 250 nl/min flow rate, where mobile phase A was 0.1% formic acid in water 479 
and mobile phase B consisted of 0.1% formic acid in 80% ACN. The QExactive HF was 480 
operated in data-dependent mode where the 15 most intense precursors were selected for 481 
subsequent fragmentation. Resolution for the precursor scan (m/z 300–1600) was set to 120,000 482 
with a target value of 3 × 106 ions. MS/MS scans resolution was set to 15,000 with a target value 483 
of 1 × 105 ions. The normalized collision energy was set to 27% for HCD. Dynamic exclusion 484 
was set to 30 s, peptide match was set to preferred, and precursors with unknown charge or a 485 
charge state of 1 and ≥ 7 were excluded. Data Analysis: Raw data files were processed using 486 
Proteome Discoverer version 2.1 (Thermo Fisher Scientific). Peak lists were searched against a 487 
reviewed Uniprot human database, appended with a common contaminants database, using 488 
Sequest. The following parameters were used to identify tryptic peptides for protein 489 
identification: 10 ppm precursor ion mass tolerance; 0.02 Da product ion mass tolerance; up to 490 
two missed trypsin cleavage sites; phosphorylation of Ser, Thr and Tyr were set as variable 491 
modifications. The ptmRS node was used to localize the sites of phosphorylation. Peptide false 492 
discovery rates (FDR) were calculated by the Percolator node using a decoy database search and 493 
data were filtered using a 5% FDR cutoff. The peak areas for the identified peptides were 494 
extracted and used for relative quantitation across samples. 495 
 496 
Site directed mutagenesis, in vitro assembly, transfections, and immunofluorescence. 497 
Mutagenesis of GFAP (Origene, Rockville, MD, in vector CMV6-XL6) was performed using the 498 
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QuikChange II mutagenesis kit (Agilent) to generate the designated point mutants. Sanger 499 
sequencing of the entire coding sequence of GFAP was performed to confirm the wild-type and 500 
mutant sequences. We used established procedures for the purification and in vitro assembly of 501 
GFAP
61
. For transfections, lipofectamine 2000 was used according to the supplier instructions 502 
(Invitrogen, Thermo Fisher Scientific, Carlsbad, CA), and experiments were performed 20-24 503 
hours after transfection. For immunofluorescence, cells were fixed in methanol at -20°C for 10 504 
minutes, washed three times in PBS and incubated in blocking solution (2.5% bovine serum 505 
albumin, 2% normal goat serum in PBS) for 1 hour at room temperature. Primary antibodies 506 
were diluted into blocking buffer and incubated overnight at 4°C. The next day, cells were 507 
washed 3 times in PBS and incubated with Alexa Fluor-conjugated secondary antibodies diluted 508 
into blocking buffer for 1 hour at room temperature. Cells were washed 3 times in PBS, 509 
incubated in DAPI for 5 minutes, washed 3 times and mounted in Fluoromount-G 510 
(SouthernBiotech, Birmingham, AL) overnight. Cells were imaged on Zeiss 880 confocal laser 511 
scanning microscope using a 63x (1.4 NA) oil immersion objective (Zeiss, Jena, Germany).  512 
 513 
Preparation of protein lysates and western blotting. High salt extracts (HSEs) and triton-X 514 
(TX) lysates were prepared as previously described
59
. Total lysates were prepared by 515 
homogenizing 25mg tissue directly into hot 2X Tris-Glycine SDS Sample Buffer (Thermo Fisher 516 
Scientific) and heating for 5 minutes at 95°C. Immunoblotting was performed as previously 517 
described
62
. Briefly, samples were resolved on 4-20% gradient SDS-PAGE gels transferred onto 518 
activated polyvinylidene difluoride membranes at 40V overnight. The transferred gels were 519 
routinely stained with Coomassie blue and the membranes were blocked in 5% non-fat milk in 520 
0.1% tween 20/PBS (PBST). Post-transfer Coomassie-stained gels served as another loading 521 
control where the levels of housekeeping protein (actin) varied (Fig. 4E). For immunoblotting, 522 
the membranes were incubated with the appropriate primary antibody diluted in 5% milk/PBST, 523 
with the exception of KT13, which was incubated in 5% bovine serum albumin/PBST for 524 
blocking, primary antibodies and secondary antibodies. Antibodies were detected using ECL 525 
reagents (PerkinElmer Life Sciences, Hopkinton, MA). For 2D gel analysis, HSEs were 526 
dissolved in 2-D starter kit rehydration/sample buffer (Biorad; 1632106) for separation by 527 
isoelectric focusing (IEF). Immobilized pH gradient (IPG) strips (Biorad; 11 cm; pH 4-7; 528 
1632015) were passively rehydrated in 2-D starter kit rehydration/sample buffer overnight. Cup 529 
loading method was employed to load the protein samples in cathode side (as isoelectric point of 530 
GFAP is 5.2) of the Protean IEF cell tray (Biorad; 1654020). The IEF separation was done using 531 
72000 vh. After IEF separation the protein samples were further parted based on molecular 532 
weight using SDS-PAGE gel by applying constant 90 volts. 533 
 534 
Cellular reprogramming, characterization and karyotyping of iPSCs. Skin fibroblasts were 535 
reprogrammed under feeder free conditions using Cytotune –iPS 2.0 Sendai Reprogramming kit 536 
and individual iPSC clones were picked for propagation in culture for 10 passages. To confirm 537 
stemness and differentiation capabilities of reprogrammed and edited iPSCs, we used the qPCR 538 
based TaqMan human Pluripotent Stem Cell Scorecard Panel (Thermo Fisher Scientific). iPSCs 539 
were differentiated into all three germ layers using STEMdiff Trilineage Differentiation Kit 540 
(StemCell Technologies, Vancouver, Canada), and a monolayer-based protocol was used to 541 
directly differentiate hES cells in parallel into the three germ layers (~1 week). Non-542 
differentiated and differentiated cells were lysed and total RNA purified using the RNeasy kit 543 
(QIAGEN). RNA reverse transcription was performed following the Taqman Scorecard’s 544 
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manufacture guidelines and the qRT-PCR was carried out using the QuantStudio 7 Flex Real-545 
Time PCR system. The TaqMan PCR assay combines DNA methylation mapping, gene 546 
expression profiling, and transcript counting of lineage marker genes
63
. Reprogrammed and 547 
edited iPSCs were submitted to a standard G-band analysis consisting of 20 metaphase spreads. 548 
The analysis was carried out by Karyologic Inc. The analysis can identify gender, chromosome 549 
number, and detect aberrations that include trisomies, monosomies, deletions, insertions, 550 
translocations, duplications, breaks, polyploidy, among others. No abnormalities were found in 551 
our cell lines (Supplemental Fig.2A). 552 
 553 
CRISPR/Cas9 genome editing. We used the TrueCut Cas9 Protein V2, sgRNAs and the Neon 554 
Transfection system (Thermo Fisher Scientific) to edit iPSCs. The recombinant TrueCut Cas9 555 
V2 was diluted in resuspension buffer R provided in the kit and mixed with 900ng of sgRNA and 556 
2700ng of single-stranded donor oligonucleotide, incubated 15 minutes at room temperature and 557 
then a total of 3x10
5
 iPSCs were electroporated with the ribonucleoprotein mix. Seventy-two 558 
hours after electroporation, cells were dissociated into single cells, diluted, and seeded on 559 
Matrigel-coated 96-well plates. Single-cell colonies were selected after two weeks and tested for 560 
gene correction. Genomic DNA of single clones was extracted and the gene of interested 561 
amplified by PCR using allele specific primers. Sanger sequencing of positive clones 562 
demonstrated single or double allele gene correction. Off-target sites within the exons of genes 563 
were predicted via selection of the top candidates using the MIT software (CRISPR.mit.edu). 564 
The analysis was performed via PCR of 400bp fragments, which flanked the predicted off-target 565 
cut site followed by Sanger sequencing. The chromatograms for edited clones were compared to 566 
sequences from the original AxD patient cells.  567 
 568 
iPSC culture and astrocyte differentiation. iPSCs were maintained on Matrigel in Stem Flex 569 
medium (Thermo Fisher Scientific) and passaged every 3-4 days with 0.5 mM EDTA 570 
dissociation solution. iPSCs were differentiated into neural progenitor cells (NPC) using an 571 
embryoid body (EB) protocol. Briefly, iPSCs at 80% confluence were collected, resuspended in 572 
Neural Induction Medium (NIM, StemCell Technologies) and seeded on one well of an 573 
Aggrewell 800 plate (StemCell Technologies) at 3x10
6
 cells per well. At day five, EBs were 574 
seeded on poly-ornithine and laminin (PLO/LAM)-coated dishes in NIM. Rosette selection was 575 
performed after 12 days using Rosette Selection Reagent (StemCell Technologies). NPCs were 576 
expanded for 7 days in Neural Progenitor Medium (StemCell Technologies). NPCs were then 577 
differentiated into astrocyte precursors by seeding dissociated single cells at 1x10
5
 cells/cm
2
 578 
density on PLO/LAM dishes in STEMdiff astrocyte differentiation medium (StemCell 579 
Technologies). Astrocyte precursors were maintained for 20 days with medium changes every 48 580 
hours and splitting every week with Accutase (Millipore, Burlington, MA). Astrocytes were 581 
expanded for up to 120 days in STEMdiff astrocyte maturation medium (StemCell 582 
Technologies).  583 
 584 
Transmission Electron Microscopy. AxD iPSC-astrocytes grown on a polystyrene dish were 585 
fixed in 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer, pH 7.4, for one hour at room 586 
temperature and stored at 4 ̊C.  The cells were washed 3 times in 0.1M sodium cacodylate buffer 587 
followed by post-fixation in 1% buffered osmium tetroxide for 1 hour.  After 3 washes in 588 
deionized water, the cells were dehydrated in ethanol, infiltrated and embedded in situ in 589 
PolyBed 812 epoxy resin (Polysciences, Inc., Warrington, PA).  The cell monolayer was 590 
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sectioned en face to the substrate with a diamond knife and Leica UCT Ultramicrotome (Leica 591 
Microsystems, Inc., Buffalo Grove, IL).  Ultrathin sections (70nm) were mounted on 200 mesh 592 
copper grids and stained with 4% uranyl acetate and lead citrate.  The sections were observed 593 
and digital images were taken using a JEOL JEM-1230 transmission electron microscope 594 
operating at 80kV (JEOL USA, Inc., Peabody, MA) equipped with a Gatan Orius SC1000 CCD 595 
Digital Camera (Gatan, Inc., Pleasanton, CA). 596 
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FIGURES & LEGENDS 821 
 822 
Figure 1. GFAP is phosphorylated on head domain Ser13 in human AxD brain.  A. 823 
Schematic displays the frequency and location of AxD patient GFAP mutations. B. Method used 824 
to identify GFAP phospho-peptides. C. Graph of AxD-specific GFAP phospho-peptides 825 
identified by mass spectrometry and type/position of patient mutations. PSM=peptide spectrum 826 
match. Green diamonds represent GFAP mutations in young patients (median age at death=1.7 827 
years; range 0.5-14 years) and pink diamonds represent older patients (median age at 828 
death=38 years; range 27-50 years). D. Amino acid conservation at the N-terminus of human, 829 
rat and mouse GFAP. The green box indicates the serine corresponding to human Ser13, which 830 
is conserved in rat and mouse.  831 
 832 
Figure 2. GFAP is phosphorylated on head domain Ser13 primarily in AxD brain from 833 
young patients. A. Quantification of pSer13-GFAP abundance by mass spectrometry in young 834 
(green) vs. old (pink) AxD patients (* = p<0.05 unpaired t-test). B. Validation of pSer13-GFAP 835 
by western blot of HSE from AxD patients, using a phospho-specific antibody to pSer13-GFAP. 836 
The order of samples, by AxD donor ID number, is: 1482, 1070, 885, 5488, 1161, 2768, 338, 837 
613, 5377, 5517, M3596, 5109, and 4858 (listed in Supplemental File 1).  C. Quantification of 838 
the relative intensity of pSer13-GFAP on western blot in young (green) and old (pink) AxD 839 
patients (* = p<0.05 unpaired t-test). Signal intensity was normalized to total GFAP in each 840 
sample. D. Western blot of pSer13-GFAP in non-AxD control brain lysates of different ages. 841 
The order of samples, by AxD donor ID number, is: 1547, 5941, 103, 1791, 1670, 4898, 1706, 842 
1711, 1011, 632, 4640, and 4915 (listed in Supplemental File 2). 843 
 844 
Figure 3. Effect of phospho-deficient and phospho-mimetic mutations S13 substitutions on 845 
GFAP filament assembly in cells and in vitro. A. Representative images of 846 
immunofluorescence staining of DNA (blue) and GFAP (green) in SW13vim- cells transfected 847 
with wild-type GFAP (WT), R79H mutant GFAP (R79H), non-phosphorylatable GFAP (S13A), 848 
and phospho-mimic GFAP (S13D and S13E) as single or double mutations, as noted in the 849 
images. Scale bar=5µm. B.  Quantification of percentage of cells containing GFAP filaments, 850 
aggregates or both (n = 41-103 cells per condition). RH=R79H; SA=S13A; SD=S13D; 851 
SE=S13E. C. Electron micrographs showing the filament properties of in vitro assembled GFAP 852 
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(WT, S13A and S13D). Bottom 3 panels represent magnified areas marked by the white boxes in 853 
the top panels. Scale bars=500nm. 854 
 855 
Figure 4. Generation and characterization of AxD patient iPSC-astrocytes and isogenic 856 
controls. A. Characterization of iPSC pluripotency. Bright field images of AxD patient 857 
fibroblasts (top left) and iPSCs (bottom left).  Immunofluorescence staining for pluripotency 858 
markers in AxD iPSCs. B. GFAP sequence for the AxD mutant allele and the corrected allele. 859 
Differences between the sequences are indicated by red text. The AxD-causing mutation is 860 
underlined, and all other changes are silent mutations. The area of gRNA recognition is indicated 861 
by the red line. C. Chromatograms showing AxD heterozygous mutation in the original patient 862 
cells (top), correction of the mutant allele in the isogenic control (middle) and correction of the 863 
wild-type allele in the CRISPR control (bottom). Red arrows denote presence of the disease 864 
mutation and green check mark denote genetic correction and presence of silent mutations. D. 865 
Schematic representation of astrocyte differentiation protocol. NIM, neural induction medium; 866 
NPM; neural progenitor medium; ADM, astrocyte differentiation medium; AMM; astrocyte 867 
maturation medium. E. Immunoblot of GFAP in iPSC-astrocytes. Pan-actin blot and Coomassie 868 
stain serve as loading controls. F. Quantification of band intensities for GFAP from panel E. 869 
****p<0.0001 compared to isogenic control; one-way ANOVA. 870 
 871 
Figure 5. Oligomerization and perinuclear aggregation of GFAP in AxD iPSC-astrocytes.    872 
A. GFAP blot of AxD iPSC-astrocytes (left) and SW13vim- cells transfected with R239C mutant 873 
GFAP (right) reveals GFAP monomer and high molecular mass GFAP oligomers. Immunoblots 874 
on the bottom are of the same membranes at lower exposure. B. Immunofluorescence staining 875 
for GFAP (magenta) and DAPI (white) in AxD iPSC-astrocytes reveals presence of perinuclear 876 
GFAP aggregates, marked by the yellow arrows. Scale bars=10µm. Boxed area in the merged 877 
image is shown by the enlarged image on the right. C. Immunofluorescence staining for GFAP 878 
(magenta) and DAPI (white) in isogenic control iPSC-astrocytes. Scale bars=10µm. 879 
 880 
Figure 6. pSer13 marks perinuclear accumulation of GFAP within nuclear invaginations in 881 
AxD iPSC-astrocytes. A. Immunofluorescence staining of total GFAP (magenta), pSer13-GFAP 882 
(green) and DAPI (blue) in isogenic control (top panels) and AxD mutant (bottom panels) iPSC-883 
astrocytes. Perinuclear GFAP aggregates are indicated by the yellow arrows. Scale bars=10µm. 884 
B. Electron microscopy images of AxD patient iPSC-astrocytes revealing large, juxtanuclear 885 
fibrous bundles (boxed area on left), shown at higher magnification on the right. Scale bar=5µm 886 
(left) and 0.5µm (right).  887 
 888 
Figure 7. Phosphorylation of Ser13 on GFAP promotes caspase-6 cleavage of GFAP. A. 889 
GFAP blot of SW13vim- cells transfected with vector, WT, S13A, S13D and S13E - GFAP. 890 
Full-length (fl) and cleaved fragment (cf) of GFAP are indicated by arrows. Immunoblot on the 891 
bottom shows GFAP monomer (fl) from the same membrane at a lower exposure. B. 892 
Quantification of panel A by densitometry shows cleaved and full-length GFAP in phospho-893 
mutants relative to WT GFAP (mean ± SD from 3 independent experiments; *p<0.05 two-way 894 
ANOVA). C. GFAP blot in SW13vim- cells transfected with either S13D or S13D/R79H double 895 
mutant GFAP and treated for 48hr with a caspase-6 inhibitor (Ac-VEID-CHO). D. 896 
Quantification of GFAP bands in panel C by densitometry (mean ± SD from 3 biological 897 
replicates; **p<0.01; ****p<0.0001 two-way ANOVA). E. Immunoblot for GFAP monomer (fl) 898 
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and cleaved fragment (cf) in isogenic control and AxD iPSC-astrocytes. Different amounts of 899 
total protein were loaded to normalize GFAP monomer levels. F. Immunofluorescence staining 900 
of caspase-6 (magenta), GFAP (green) and DAPI (blue) in human AxD and isogenic control 901 
iPSC-astrocytes showing caspase-6 co-localization within GFAP aggregates in the AxD cells, 902 
indicated by the arrowheads. Scale bars=20µm. 903 
 904 
Figure 8. Inhibition of GFAP cleavage by caspase-6 partially alleviates aggregation due to 905 
S13D phospho-mimic mutation. A. Western blot of GFAP total cell lysates from SW13vim- 906 
cells transfected with empty vector control, WT, S13D, D225E, and double S13D/D225E 907 
mutants. Shown are GFAP cleaved fragment (cf), full-length (fl) monomer and pan-actin 908 
(loading control). B. Quantification of the abundance of cleaved GFAP in the three mutants 909 
shown in panel A relative to WT GFAP (mean ± SD from 3 biological replicates; ****p<0.0001 910 
compared to S13D; one-way ANOVA). C. Representative images of immunofluorescence 911 
staining of DNA (blue) and GFAP (green) in SW13vim- cells transfected with wild-type GFAP 912 
(WT), phospho-mimic GFAP (S13D), and non-cleavable GFAP (D225) as single or double 913 
mutations, as noted in the images. Scale bar=10µm. D.  Quantification of percentage of cells 914 
containing GFAP filaments, aggregates or both (n = 76-85 cells per condition). E. Representative 915 
images of immunofluorescence staining of DNA (blue) and GFAP (green) in SW13vim- cells 916 
transfected with wild-type GFAP (WT) or phospho-mimic GFAP (S13D) and treated with 917 
vehicle (control) or the caspase-inhibitor Ac-VEID-CHO (10µM, 48h). F. Western blot analysis 918 
of SW13vim- total lysates transfected with S13D GFAP and treated with vehicle (control) or 919 
caspase-6 inhibitor Ac-VEID-CHO (10µM, 24h), showing the 24 kDa caspase-cleaved fragment 920 
(cf), 50kDa full-length (fl), and high-molecular-mass (hmm) ~100kDa GFAP. G. Quantification 921 
of the relative abundance of hmm GFAP in control and Ac-VEID-CHO – treated cells. n=3; 922 
**p<0.01; unpaired t-test. 923 
 924 
Figure 9. High expression of caspase-6 in young AxD patient brain tissue correlates with 925 
increased levels of cleaved GFAP. A. Immunoblot for caspase-6 in total lysates from human 926 
AxD post mortem brain tissue shows that caspase is upregulated in young AxD patients. Pan-927 
actin is used as a loading control. B. Immunoblot for caspase-6 in total lysates from young and 928 
old non-AxD control and AxD patient post-mortem brain tissue. Pan-actin blot serves as a 929 
loading control. C. Quantification of band intensities in panel B by densitometry of caspase-6 930 
normalized to actin. ****p<0.0001; two-way ANOVA. D. Western blotting for full-length 931 
GFAP or cleaved GFAP (D225 antibody) in HSEs from human AxD post-mortem brain tissue. 932 
E. Quantification of band intensities from panel D by densitometry of D225, normalized to total 933 
GFAP (**p<0.01, unpaired t-test). F. Immunofluorescence staining showing widespread 934 
presence of cleaved GFAP (D225; magenta) in cerebral cortex and underlying white matter of 935 
347 day-old child with AxD and low expression of cleaved GFAP in a 42 year old AxD patient. 936 
Wider fields of view and sections from additional patients are shown in Figure 7-Supplement 1. 937 
DAPI nuclei are shown in white in bottom panels, and arrow highlights perinuclear aggregate 938 
containing cleaved GFAP and staining positively for DAPI in brain tissue from a child with 939 
AxD. Scale bar=100µm (top) and 10µm (bottom). 940 
 941 
FIGURE SUPPLEMENTS 942 
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Figure 1-Supplement 1. Preparation of brain high salt extracts (HSE) for mass 943 
spectrometry analysis of GFAP. Isolation of intermediate filament proteins using high salt 944 
extraction. Shown is an abbreviated version of the protocol referenced in Materials and Methods. 945 
Adopted from Snider & Omary, Methods in Enzymology 2016. In the panel on the right, purified 946 
GFAP is resolved in parallel with a representative HSE from an AxD patient brain cortex tissue. 947 
Arrow points to the band that was excised for MS/MS phospho-proteomic analysis. 948 
Figure 3-Supplement 1. Optimization of transient expression for WT and AxD-associated 949 
GFAP mutant proteins in SW13vim- cells. A. Western blot of SW13vim- cells transfected for 950 
24h with the designated GFAP constructs. NTC, non-transfected control. Top and bottom blots 951 
show GFAP and pan-actin, respectively, in the Triton X-100-soluble fraction (TX-100). Middle 952 
blot is a total cell lysate (TCL) blot of GFAP from the same transfections. B. Corresponding 953 
immunofluorescence staining of GFAP in SW13vim- cells after 24h of transfection. Scale 954 
bars=10µm. 955 
Figure 4-Supplement 1. Characterization of pluripotency in AxD and isogenic control 956 
iPSCs. A. Karyotype analysis for original AxD patient iPSCs, isogenic control (MDCL11) and 957 
CRISPR control (MDCL14) iPSCs showing normal karyotypes for all three clones. B. 958 
Immunofluorescence staining for iPSC pluripotency markers (red/green) and DAPI (blue). Scale 959 
bars=400µm. C. TaqMan hPSC Scorecard Panel that compares the gene expression profile of the 960 
generated iPSCs against 9 reference lines. Heat map of the genes that are up-regulated (red), 961 
have the same expression level (white) or are down -regulated (blue) in the iPSCs. Colors 962 
correlate to the fold change in expression of the indicated gene relative to the undifferentiated or 963 
Day 7 embryoid body (EB) differentiated reference set. Shown at the bottom are differentiation 964 
index plots of changes in self-renewal genes (green) and differentiation genes (blue-ectoderm, 965 
orange-mesoderm, purple-endoderm) in the 1 week EB differentiated cells (left) and 966 
undifferentiated cells (right). 967 
Figure 4-Supplement 2. Characterization of astrocyte differentiation. A. 968 
Immunofluorescence staining for astrocyte markers ALDH1L1 and SLC1A3 (green) and DAPI 969 
(blue) in isogenic control, CRISPR mutant and AxD iPSC-astrocytes. Scale bars=20µm. B. 970 
Immunofluorescence staining for astrocyte markers GFAP (magenta), Connexin-43 (green, top), 971 
EAAT2 (green, bottom) and DAPI (blue) in AxD iPSC-astrocytes. Scale bars=10µm. 972 
Figure 6-Supplement 1. Three types of staining pattern observed with the pSer13 GFAP 973 
antibody in AxD iPSC-astrocytes. Three types of cells were observed with respect to pSer13 974 
signal: Type I: primarily aggregates (arrows); Type II: aggregates and soluble cytoplasmic GFAP 975 
(asterisk) and Type III: aggregates and filamentous GFAP (arrowheads).  976 
Figure 7-Supplement 1. Analysis of major sites of phosphorylation on R79H GFAP 977 
expressed in SW13 vim- cells. A. Coomassie stain of a HSE extracts from WT and R79H GFAP 978 
analyzed by 2-dimensional (2D) gel electrophoresis. Red arrow points to a negatively charged 979 
species that was only present in R79H and analyzed by mass spectrometry. B. Summary of 980 
phosphorylation state of the negatively charged GFAP species from panel A. C. Effect of 981 
phospho-deficient mutants S16A and S17A on GFAP R79H oligomerization and cleavage.  982 
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Figure 9-Supplement 1. Presence of cleaved GFAP in in post-mortem brain tissue of AxD 983 
children versus adults. Human brain sections were immunostained with the D225 antibody, 984 
which recognizes the N-terminal fragment of cleaved GFAP at Asp-225.  985 
 986 
Supplemental File 1. Donor information for AxD post-mortem human brain specimens. 987 
 988 
Supplemental File 2. Donor information for control (non-AxD) post-mortem human brain 989 
specimens. 990 
 991 
Supplemental File 3. Summary from off-target sequencing from CRISPR/Cas9 editing.  992 
 993 
Supplemental File 4. GFAP phosphorylation motifs and candidate kinases. 994 
 995 
Source Data: Figure 2-Source Data 1: Raw data from mass spectrometry PTM profiling of 996 
GFAP extracted from AxD and control human brain. 997 
 998 
Source Data: Figure 7-Source Data 1: Raw data from mass spectrometry PTM profiling of 999 
GFAP R79H extracted from transfected SW13vim-cells.  1000 
 1001 









